|2.||Breast Neoplasms (Breast Cancer)
|3.||Neoplasm Metastasis (Metastasis)
|4.||Ovarian Neoplasms (Ovarian Cancer)
|5.||Endometrial Neoplasms (Endometrial Cancer)
|1.||Salvesen, Helga B: 48 articles (02/2016 - 01/2002)|
|2.||Sakuragi, Noriaki: 45 articles (10/2014 - 05/2002)|
|3.||Cohn, David E: 40 articles (09/2015 - 12/2002)|
|4.||Leslie, Kimberly K: 37 articles (10/2015 - 02/2002)|
|5.||Mutch, David G: 36 articles (07/2015 - 06/2002)|
|6.||Broaddus, Russell R: 35 articles (01/2016 - 09/2002)|
|7.||Lu, Karen H: 35 articles (12/2015 - 10/2003)|
|8.||Goodfellow, Paul J: 35 articles (02/2015 - 06/2002)|
|9.||Aoki, Daisuke: 32 articles (11/2015 - 03/2002)|
|10.||Dowdy, Sean C: 30 articles (02/2016 - 10/2004)|
06/01/2014 - "Unless the patient has been identified to be at high risk of endometrial cancer, routine endometrial surveillance has not proved to be effective in increasing the early detection of endometrial cancer in women using tamoxifen and is not recommended. "
07/01/2001 - "Although the incidence of endometrial cancer associated with tamoxifen use is not high, the risk is true and these patients could be helped by screening methods such as transvaginal ultrasonogrphy. "
02/01/1996 - "Tamoxifen was effective in treating patients with endometrial cancer. "
04/01/1990 - "We previously showed that combined treatment with tamoxifen and progestin was effective in arresting the growth of human endometrial carcinomas in the nude mouse model. "
03/01/1999 - "It is not known which endometrial carcinomas will respond favorably to tamoxifen and which ones will not. "
|2.||Paclitaxel (Taxol)FDA LinkGeneric
01/01/2003 - "The best treatment for recurrent endometrial cancer is still uncertain, although weekly paclitaxel has shown some promise in the management of this disease. "
09/01/2014 - "Concurrent chemoradiation with weekly paclitaxel is well tolerated and seems to be effective for high-risk endometrioid endometrial cancers. "
03/01/2010 - "These results, based on a larger series, support our previous data: Paclitaxel plus RT may represent an effective and well-tolerated treatment in high-risk endometrial cancer patients."
04/01/2015 - "AURKA is a promising therapeutic target in endometrial cancer and the combination therapy with AURKA inhibitors and paclitaxel could be effective for endometrial cancer that is resistant to conventional treatment and has a poor prognosis."
02/01/2003 - "The aim of this study was to evaluate the toxicity and efficacy of weekly paclitaxel in patients with recurrent endometrial cancer. "
|3.||Estrogens (Estrogen)FDA Link
09/30/1994 - "Further work is needed to identify one or several progestogen-regulated markers that most closely correlate with protection against estrogen-induced endometrial cancer."
10/01/2012 - "While exposure to estrogens is a major risk factor of breast and endometrial cancer, it well established that estrogens are beneficial for bone health. "
03/01/1979 - " The addition of synthetic progestin to estrogen therapy provided significant (p .001) protection against the likelihood of developing endometrial cancer and did not reduce previously reported metabolic benefits of estrogen treatment. "
03/01/1979 - "The addition of synthetic progestin to estrogen therapy provided significant protection against the likelihood of developing endometrial cancer and did not reduce previously reported metabolic benefits of estrogen treatment. "
03/01/2011 - "In breast and endometrial carcinomas, panels of estrogen-induced genes have shown improved prognostic capability over the use of ER immunohistochemistry alone. "
|4.||Carboplatin (JM8)FDA LinkGeneric
03/01/1996 - "We conclude that a regimen of carboplatin plus sequential hormonal therapy shows promise in this pilot study for the treatment of advanced or recurrent endometrial cancer."
01/01/2003 - "Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. "
01/01/1997 - "Continuous local injection of carboplatin into the uterine cervix for cervical and endometrial cancer: preliminary study."
02/01/1992 - "The role of carboplatin in cervical and endometrial cancers is being assessed through clinical trials. "
04/01/1990 - "A phase II study of the effectiveness and toxicity of carboplatin in the treatment of metastatic or locally advanced endometrial cancer was carried out by the Southwest Oncology Group. "
01/01/2010 - "Treatment with hormones is thought to be beneficial in patients with endometrial cancer. "
10/01/1991 - "A new treatment for endometrial cancer with gonadotrophin releasing-hormone analogue."
01/01/2011 - "This study evaluated the feasibility and efficacy of combined operative hysteroscopy (HSC) and hormone therapy as fertility-preserving treatment in a cohort of selected young women with early endometrial carcinoma (EC). "
01/01/1993 - "One can conclude that adjuvant hormone therapy in endometrial carcinoma patients who have unfavourable prognosis of the disease must be administered for not less than 3 years in order to obtain prolongation of remission of the disease."
10/01/1988 - "Efficacy of sequential cyclical hormonal therapy in endometrial cancer and its correlation with steroid hormone receptor status."
12/01/2013 - "Progesterone therapy has been shown to be effective in preventing endometrial cancer as well as controlling growth of the endometrium. "
01/01/2010 - "This review highlights what is known thus far regarding the efficacy of progestin therapy in the clinic and the role of progesterone in endometrial cancer cell behavior and gene regulation."
05/01/1998 - "We hypothesized that the hPRA:hPRB ratios may be abnormal in endometrial cancer, leading to a lack of normal progesterone protection against the growth-promoting effects of E2. "
04/01/1994 - "The efficacy of progesterone in treating patients with endometrial carcinoma is well known. "
09/01/2015 - "The observed increased risk of endometrial cancer associated with progesterone-only therapy merits further study."
12/01/2001 - "Premenopausal women--especially young women--with endometrial cancer stage I may be treated successfully with progestins alone as primary therapy to preserve their child-bearing potential. "
04/01/2008 - "Primary treatment with either oral or intra-uterine progestagens to preserve fertility in younger women with endometrial carcinoma is effective in about 70% of cases. "
06/01/2001 - "The concept that hormonal therapy may be useful in the treatment of endometrial cancer antedated the pharmaceutical availability of progestational compounds. "
12/01/1999 - "Does it really offer as much protection against endometrial cancer as oral progestogens do?"
09/01/1979 - "Reduced incidence of endometrial cancer among postmenopausal women treated with progestogens."
09/01/2015 - "Use of oral contraceptives confers long-term protection against endometrial cancer. "
08/13/1982 - "Protection against endometrial carcinoma by combination-product oral contraceptives."
01/22/1982 - "Protection against endometrial carcinoma by combination-product oral contraceptives."
08/01/1995 - "For ovarian and endometrial cancers this accords with strong evidence from person-based studies of the protective effect of oral contraceptives. "
11/01/2015 - "Endometrial cancer with progestagen and oestrogen oral contraceptives."
|9.||Cisplatin (Platino)FDA LinkGeneric
07/01/2011 - "[Establishment of cisplatin-resistant human endometrial cancer cell line and the study of its resistant mechanisms]."
01/01/2007 - "The unexpectedly long survival seen in this cohort supports a phase II trial of IPHC with cisplatin for recurrent endometrial cancer."
11/01/2006 - "The primary objective of this study was to determine the mechanism(s) of cisplatin drug resistance in endometrial cancer cell lines. "
12/01/1996 - "A Gynecologic Oncology Group Phase I study was designed to evaluate the toxicity of whole abdominal radiation therapy with concurrent weekly cisplatin in patients with surgical International Federation of Gynaecology and Obstetrics (FIGO) Stage III and IV endometrial carcinoma. "
12/01/1996 - "A phase I study of weekly cisplatin and whole abdominal radiation for the treatment of stage III and IV endometrial carcinoma: a Gynecologic Oncology Group pilot study."
|10.||Doxorubicin (Adriamycin)FDA LinkGeneric
08/01/2005 - "In this trial, liposomal doxorubicin had a response rate of 11.5% in first-line treatment of disseminated endometrial carcinoma when given at 40 mg/m(2) every 4 weeks. "
11/01/2011 - "This phase 2 study was designed to evaluate the objective response rate and the toxicity profile of Myocet in women with advanced or recurrent endometrial cancer. "
11/01/2011 - "Phase 2 trial of nonpegylated doxorubicin (Myocet) as second-line treatment in advanced or recurrent endometrial cancer."
08/01/2005 - "Phase II trial of liposomal doxorubicin at 40 mg/m(2) every 4 weeks in endometrial carcinoma: a Gynecologic Oncology Group Study."
10/01/2004 - "Study design Three ovarian (SKOV-3, NIH:OVCAR-3, EFO-21) and 2 endometrial carcinoma cell lines (Ishikawa, HEC-1A) were evaluated for doxorubicin- or AN-152-induced apoptosis. "
|1.||Drug Therapy (Chemotherapy)
06/01/2014 - "The purpose of this review is to analyze clinical evidence about the activity and efficacy of anthracycline-based chemotherapy in metastatic endometrial cancer and to identify the most important preclinical findings that would address future clinical trials. "
05/01/2013 - "In the current study of surgically staged patients with type II endometrial carcinoma International Federation of Gynecology and Obstetrics stages I and II, adjuvant radiation therapy with or without chemotherapy resulted in a significant improvement in recurrence-free and disease-specific survival."
06/01/2013 - "Our findings suggest that combined OATP1B3/CTR1 expression is a possible predictive/prognostic factor for a good outcome in stage III endometrial cancer patients treated with adjuvant TC chemotherapy."
10/01/2015 - "This study aimed to assess primarily the role of chemotherapy as adjuvant treatment for International Federation of Gynecology and Obstetrics (FIGO) stage IA G3, IB G2-G3, and II endometrial cancer (EC) in terms of disease-free interval and overall survival, and secondarily, the rate of local and distant recurrence. "
10/01/2010 - "Concomitant postoperative radiation and chemotherapy following surgery was associated with improved overall survival in patients with FIGO stages III and IV endometrial cancer."
|2.||Lymph Node Excision (Lymph Node Dissection)
07/01/2013 - "Lymphadenectomy in endometrial cancer is beneficial in stages I G3, II and III. In stages I G1 and G2 an increase in the survival time has not been shown. "
07/01/2012 - "In women older than 80, systematic lymphadenectomy is associated with improved DSS for high grade, but similar DSS for low grade endometrial cancer, consistent with what is seen with younger women. "
05/01/2012 - "These findings suggest that the efficacy of systematic lymphadenectomy, defined as removal of more than about 10 lymph nodes, is limited for improving overall survival in patients with low-risk endometrial cancer, whereas it is efficient to increase overall survival in patients with intermediate- or high-risk endometrial cancer."
01/01/2013 - "According to the results, systematic pelvic and para-aortic lymphadenectomies improved disease-free and overall survival rates among the patients with endometrial cancer. "
05/01/2012 - "The efficacy of systematic lymphadenectomy is controversial for improving overall survival in patients with endometrial cancer. "
05/01/2009 - "Adjuvant pelvic and/or whole abdominal radiotherapy have not been shown to be clearly beneficial in women diagnosed with clear cell endometrial cancer. "
12/01/2002 - "Adjuvant postoperative radiotherapy in an intermediate-risk group of endometrial cancer patients resulted in improvement in local control, but survival was not improved significantly. "
08/01/2001 - "Patients with endometrial cancer who have not previously received pelvic irradiation and develop isolated pelvic recurrences can be effectively treated with pelvic radiotherapy. "
06/01/1998 - "Preoperative radiotherapy followed by surgery is a safe and effective treatment of FIGO stage I or II endometrial carcinomas. "
12/01/2010 - "The efficacy of postoperative radiotherapy (RT) in the treatment of early-stage endometrial carcinoma (EC) is still under debate. "
12/01/2009 - "Robotic surgery dramatically altered our management of endometrial cancer and was associated with a significant improvement in several perioperative outcomes when compared to laparotomy and laparoscopy."
12/01/2014 - "Laparoscopy is a safe alternative to laparotomy for low risk endometrial cancer patients and offers markedly improved perioperative outcomes with a lower reoperation rate and fewer postoperative complications when the standard of care shifts from open surgery to laparoscopy in a university hospital."
07/01/2015 - "The aim of this study was to compare the long-term safety and efficacy of laparoscopic surgery and laparotomy for high-risk endometrial cancer (EC).A retrospective analysis based on our decade of clinical data of patients with high-risk EC who were comprehensively surgically staged by laparotomy or laparoscopy was performed. "
07/01/2013 - "We conclude that, compared with laparotomy, laparoscopic surgery seems to be beneficial in women with endometrial cancer, in particular insofar as postoperative complications and length of hospital stay. "
10/01/2005 - "In early stage endometrial cancer, the laparoscopic approach provides significant benefits compared with laparotomy in terms of QoL."
11/01/1998 - "The objective of this study was to determine the efficacy of high-dose-rate (HDR) brachytherapy in 36 medically inoperable patients with stage I endometrial cancer. "
01/15/1997 - "This study aimed to evaluate the efficacy of high-dose-rate brachytherapy (HDRB) in the primary treatment of endometrial carcinoma. "
08/01/2004 - "To determine the efficacy of high-dose rate brachytherapy as adjuvant treatment for Stage I/II papillary serous or clear cell endometrial cancer. "
08/01/1998 - "There is no suggestion that the addition of a vaginal cuff brachytherapy boost to pelvic radiation is beneficial for pelvic control or disease-free survival for patients with Stage I or II endometrial cancer. "
06/01/1998 - "Intracavitary brachytherapy of primary endometrial carcinoma was improved by individualized application- and planning procedures, which led to better adaptations of the treated volumes to the target volumes. "